Scientists at Lausanne University Hospital (CHUV) and EPFL have discovered a highly potent monoclonal antibody that targets the SARS-CoV-2 spike protein and is effective at neutralizing all variants of concern identified to date, including the delta variant.
Their findings are published in the prestigious journal Cell Reports.
The newly identified antibody was isolated using lymphocytes from COVID-19 patients enrolled in the ImmunoCoV study being carried out by CHUV’s Service of Immunology and Allergy. This antibody is one of the most powerful identified so far against SARS-CoV-2. Structural characterization of the antibody indicates that it binds to an area that is not subjected to mutations of the spike protein. Through this tight interaction, the antibody blocks the spike protein from binding to cells expressing the ACE2 receptor, which is the receptor the virus uses to enter and infect lung cells. That means the antibody halts the viral replication process, enabling a patient’s immune system to eliminate SARS-CoV-2 from the body. This protective mechanism was proven through in vivo tests on hamsters; specimens that were administered the antibody were protected against infection even after receiving a highly infectious dose.
In addition to its antiviral properties, the new antibody is designed to have a lasting effect in humans. A typical unaltered antibody provides protection for up to 3–4 weeks. But this new one can protect patients for 4–6 months. That makes it an interesting preventive-treatment option for unvaccinated at-risk individuals or for vaccinated individuals who are unable to produce an immune response. Immunocompromised patients, organ transplant recipients and those suffering from certain kinds of cancer could be protected against SARS-CoV-2 by receiving antibody injections two or three times a year.
CHUV and EPFL now plan to build on these promising results in association with a start-up company which will perform clinical development and production of the antibody-containing drug, through cooperation and intellectual property agreements. Clinical trials of the drug should begin in late 2022.
Treatment or prophylaxy
This research was conducted jointly by CHUV’s Service of Immunology and Allergy, headed by Prof. Giuseppe Pantaleo and Dr. Craig Fenwick, and by EPFL’s Laboratory of Virology and Genetics, headed by Prof. Didier Trono and Dr. Priscilla Turelli. The research team was able to respond to the pandemic and discover this neutralizing antibody so quickly thanks to the multi-year support of the Swiss Vaccine Research Institute. Prof. Pantaleo’s department at CHUV also received support from the Corona Accelerated R&D in Europe (CARE) program, which is part of the Innovative Medicine Initiative (IMI) – a public-private partnership that seeks to address bottlenecks in the drug discovery and development process in Europe.
The discovery of this new antibody marks a major step forward in the fight against COVID-19. It opens the door to improved treatments for severe forms of the disease and to enhanced prophylactic measures, especially for patients with weakened immune systems. However, this antibody is not intended to replace COVID-19 vaccines, which remain the most effective way to prevent infection.
Original Article: Scientists discover a highly potent antibody against SARS-CoV-2
The Latest on: SARS-CoV-2 monoclonal antibody
- USFDA revokes emergency use status to two Covid antibody therapieson January 24, 2022 at 10:24 pm
"Because data show these treatments are highly unlikely to be active against the omicron variant, which is circulating at a very high frequency throughout the United States, these treatments are not ...
- Sars-CoV-2 spike protein activates human endogenous retroviruses in blood cellson January 24, 2022 at 6:26 am
Transposable elements, or jumping genes, are now known to be responsible for many human diseases. Keeping them repressed by methylation, RNA binding, or the attentions of the innate immune system is a ...
- Nano bubbles could treat, prevent current and future strains of SARS-CoV-2: Studyon January 23, 2022 at 10:54 pm
Now, scientists at Northwestern Medicine and The University of Texas MD Anderson Cancer Center have identified natural nano-bubbles containing the ACE2 protein (evACE2) in the blood of COVID-19 ...
- COVID: How one person’s cells led to our only antibody treatment for omicronon January 23, 2022 at 3:55 am
The blood of survivors of China’s deadly 2003 SARS CoV-1 virus holds potent immune cells that, when modified by engineers at San Francisco’s Vir Biotechnologies, is saving today’s ...
- BRIEF—Actemra cleared for SARS-CoV-2 pneumonia in Japanon January 22, 2022 at 10:27 am
This approval is based on the results from clinical studies evaluating Actemra in hospitalized patients, including an investigator-initiated, randomized, open-label, platform overseas study (RECOVERY ...
- Chugai Pharma’s Actemra gets Japanese approval for additional indication of SARS-CoV-2 pneumoniaon January 21, 2022 at 10:30 pm
Chugai Pharma’s Actemra gets Japanese approval for additional indication of SARS-CoV-2 pneumonia: Tokyo Saturday, January 22, 2022, 12:00 Hrs [IST] Chugai Pharmaceutical Co., Lt ...
- Study shows monoclonal antibody and antiviral therapy are useful in preventing the severity of SARS-CoV-2 Omicron infectionon January 21, 2022 at 6:14 am
In a new study, researchers assessed the efficacy of the FDA-approved therapeutic mAbs, as well as to small-molecule antiviral agents against the SARS-CoV-2 Omicron variant in Syrian hamsters.
- Adagio Therapeutics Summarizes ADG20 Neutralizing Activity Against SARS-CoV-2 Variants and Outlines Initiatives to Address Omicronon January 12, 2022 at 1:57 pm
Recent Publications by Several Independent Laboratories Show ADG20 Has Neutralizing Activity with Potency Comparable to Other Antibodies that Retain Activity Against Omicron Multiple Efforts Underway ...
- Optimal monoclonal antibodies against SARS-CoV-2 variantson January 10, 2022 at 7:53 pm
Researchers screen different monoclonal antibodies to identify an optimal mAb with higher binding affinity to the receptor-binding domain of SARS-CoV-2.
via Bing News
The Latest on: SARS-CoV-2 monoclonal antibody
via Google News